Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer.
Bagheri M, Mohamed GA, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, LaCroix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR
Cell Rep Med. 2024 Apr 16;5(4):101504. doi: 10.1016/j.xcrm.2024.101504. Epub 2024 Apr 8.
PMID: 38593809
Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC
Epigenomics. 2024 Mar;16(5):293-308. doi: 10.2217/epi-2023-0339. Epub 2024 Feb 15.
PMID: 38356412
Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC
bioRxiv. 2023 Jun 10; pii: 2023.06.09.544426. doi: 10.1101/2023.06.09.544426. Epub 2023 Jun 10.
PMID: 37333096
Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Bagheri M, Aisha Mohamed G, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, La Croix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR
bioRxiv. 2023 Apr 21; pii: 2023.04.19.537586. doi: 10.1101/2023.04.19.537586. Epub 2023 Apr 21.
PMID: 37131809
Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits.
Mohamed GA, Mahmood S, Ognjenovic NB, Lee MK, Wilkins OM, Christensen BC, Muller KE, Pattabiraman DR
Breast Cancer Res. 2023 Mar 1;25(1):23. doi: 10.1186/s13058-023-01621-8. Epub 2023 Mar 1.
PMID: 36859337
Quantifying epithelial-mesenchymal heterogeneity and EMT scoring in tumor samples via tyramide signal amplification (TSA).
Brown MS, Abdollahi B, Hassanpour S, Pattabiraman DR
Methods Cell Biol. 2022;171:149-161. doi: 10.1016/bs.mcb.2022.06.003. Epub 2022 Jul 26.
PMID: 35953198
Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer.
Brown MS, Abdollahi B, Wilkins OM, Lu H, Chakraborty P, Ognjenovic NB, Muller KE, Jolly MK, Christensen BC, Hassanpour S, Pattabiraman DR
Sci Adv. 2022 Aug 5;8(31):eabj8002. doi: 10.1126/sciadv.abj8002. Epub 2022 Aug 3.
PMID: 35921406
Distinct cytosine modification profiles define epithelial-to-mesenchymal cell-state transitions.
Lee MK, Brown MS, Wilkins OM, Pattabiraman DR, Christensen BC
Epigenomics. 2022 May;14(9):519-535. doi: 10.2217/epi-2022-0023. Epub 2022 Apr 6.
PMID: 35382559
Quantifying the Epithelial-to-Mesenchymal Transition (EMT) from Bench to Bedside.
Brown MS, Muller KE, Pattabiraman DR
Cancers (Basel). 2022 Feb 23;14(5) doi: 10.3390/cancers14051138. Epub 2022 Feb 23.
PMID: 35267444
Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors.
Ognjenovic NB, Bagheri M, Mohamed GA, Xu K, Chen Y, Mohamed Saleem MA, Brown MS, Nagaraj SH, Muller KE, Gerber SA, Christensen BC, Pattabiraman DR
Dev Cell. 2020 Dec 7;55(5):544-557.e6. doi: 10.1016/j.devcel.2020.10.004. Epub 2020 Oct 28.
PMID: 33120014
Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance.
Barbier V, Erbani J, Fiveash C, Davies JM, Tay J, Tallack MR, Lowe J, Magnani JL, Pattabiraman DR, Perkins AC, Lisle J, Rasko JEJ, Levesque JP, Winkler IG
Nat Commun. 2020 Apr 27;11(1):2042. doi: 10.1038/s41467-020-15817-5. Epub 2020 Apr 27.
PMID: 32341362
Recovering Gene Interactions from Single-Cell Data Using Data Diffusion.
van Dijk D, Sharma R, Nainys J, Yim K, Kathail P, Carr AJ, Burdziak C, Moon KR, Chaffer CL, Pattabiraman D, Bierie B, Mazutis L, Wolf G, Krishnaswamy S, Pe'er D
Cell. 2018 Jul 26;174(3):716-729.e27. doi: 10.1016/j.cell.2018.05.061. Epub 2018 Jun 28.
PMID: 29961576
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy.
Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, Weinberg RA
Sci Transl Med. 2018 Apr 11;10(436) doi: 10.1126/scitranslmed.aan3464.
PMID: 29643230
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells.
Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, Liu Donaher J, Reinhardt F, Chaffer CL, Keckesova Z, Weinberg RA
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346. doi: 10.1073/pnas.1618298114. Epub 2017 Mar 7.
PMID: 28270621
Emerging Biological Principles of Metastasis.
Lambert AW, Pattabiraman DR, Weinberg RA
Cell. 2017 Feb 9;168(4):670-691. doi: 10.1016/j.cell.2016.11.037.
PMID: 28187288
Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy.
Pattabiraman DR, Weinberg RA
Cold Spring Harb Symp Quant Biol. 2016;81:11-19. doi: 10.1101/sqb.2016.81.030957. Epub 2017 Jan 5.
PMID: 28057845
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.
Pattabiraman DR, Bierie B, Kober KI, Thiru P, Krall JA, Zill C, Reinhardt F, Tam WL, Weinberg RA
Science. 2016 Mar 4;351(6277):aad3680. doi: 10.1126/science.aad3680.
PMID: 26941323
Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.
Forristal CE, Brown AL, Helwani FM, Winkler IG, Nowlan B, Barbier V, Powell RJ, Engler GA, Diakiw SM, Zannettino AC, Martin S, Pattabiraman D, D'Andrea RJ, Lewis ID, Levesque JP
Leukemia. 2015 Oct;29(10):2075-85. doi: 10.1038/leu.2015.102. Epub 2015 Apr 29.
PMID: 25921247
Tackling the cancer stem cells - what challenges do they pose?
Pattabiraman DR, Weinberg RA
Nat Rev Drug Discov. 2014 Jul;13(7):497-512. doi: 10.1038/nrd4253.
PMID: 24981363
Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR, McGirr C, Shakhbazov K, Barbier V, Krishnan K, Mukhopadhyay P, Hawthorne P, Trezise A, Ding J, Grimmond SM, Papathanasiou P, Alexander WS, Perkins AC, Levesque JP, Winkler IG, Gonda TJ
Blood. 2014 Apr 24;123(17):2682-90. doi: 10.1182/blood-2012-02-413187. Epub 2014 Mar 4.
PMID: 24596419
miR-139-5p is a regulator of metastatic pathways in breast cancer.
Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, Grimmond SM, Cloonan N
RNA. 2013 Dec;19(12):1767-80. doi: 10.1261/rna.042143.113. Epub 2013 Oct 24.
PMID: 24158791
Role and potential for therapeutic targeting of MYB in leukemia.
Pattabiraman DR, Gonda TJ
Leukemia. 2013 Feb;27(2):269-77. doi: 10.1038/leu.2012.225. Epub 2012 Aug 9.
PMID: 22874877
Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb.
Zhao L, Glazov EA, Pattabiraman DR, Al-Owaidi F, Zhang P, Brown MA, Leo PJ, Gonda TJ
Nucleic Acids Res. 2011 Jun;39(11):4664-79. doi: 10.1093/nar/gkr024. Epub 2011 Feb 11.
PMID: 21317192
A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability.
Saether T, Pattabiraman DR, Alm-Kristiansen AH, Vogt-Kielland LT, Gonda TJ, Gabrielsen OS
Oncogene. 2011 Jan 13;30(2):212-22. doi: 10.1038/onc.2010.397. Epub 2010 Aug 30.
PMID: 20802522
A recessive screen for genes regulating hematopoietic stem cells.
Papathanasiou P, Tunningley R, Pattabiraman DR, Ye P, Gonda TJ, Whittle B, Hamilton AE, Cridland SO, Lourie R, Perkins AC
Blood. 2010 Dec 23;116(26):5849-58. doi: 10.1182/blood-2010-04-269951. Epub 2010 Jul 7.
PMID: 20610815
Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
Pattabiraman DR, Sun J, Dowhan DH, Ishii S, Gonda TJ
Mol Cancer Res. 2009 Sep;7(9):1477-86. doi: 10.1158/1541-7786.MCR-09-0070. Epub 2009 Sep 8.
PMID: 19737967